NMRA, REPL Lead Healthcare Surge: EPS Revisions Fuel 20%+ Gains
Neumora Therapeutics (NMRA) jumped 28.2% and Replimune Group (REPL) rose 24.3% after their forward EPS estimates were revised upward on October 29, 2026. Dream Finders Homes (DFH), Rhythm Pharmaceuticals (RYTM), and JetBlue Airways (JBLU) also posted gains of over 20% as the market validated the screener's early detection of earnings estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| NMRA | Healthcare | 2026-10-29 | +1.1pp | +28.2% |
| REPL | Healthcare | 2026-10-29 | +5.8pp | +24.3% |
| DFH | Consumer Cyclical | 2026-11-03 | N/A | +22.8% |
| RYTM | Healthcare | 2026-10-29 | N/A | +20.6% |
| JBLU | Industrials | 2026-10-29 | N/A | +20.3% |
Why did NMRA stock jump in November 2026?
NMRA jumped 28.2% (from $0.39 to $0.50) after analysts raised its forward EPS growth estimate from 30.1% to 31.1% on October 29, 2026.
The small-cap biotech's upward revision reflects improving sentiment around its pipeline, though no company-specific news was released. The gain outpaced the broader healthcare sector, indicating that the market is rewarding even modest estimate revisions in oversold names.
NMRA EPS revision history → · Screener snapshot from 2026-10-29 →
FAQ: NMRA
Why did NMRA stock jump?
NMRA stock jumped 28.2% after analysts raised its forward EPS growth estimate from 30.1% to 31.1% on October 29, 2026, and the price rose from $0.39 to $0.50.
Is NMRA a buy after the rally?
The stock remains highly speculative with a sub-$1 price, but the upward EPS revision suggests improving fundamentals; investors should consider the lack of news and small market cap.
What is NMRA's EPS growth estimate?
NMRA's forward EPS growth estimate is now 31.1% for the next year, up from 30.1% prior to the revision.
Why did REPL stock jump in November 2026?
REPL surged 24.3% (from $17.39 to $21.62) after its forward EPS growth estimate was revised from 35.3% to 41.1% on October 29, 2026.
The revision followed Replimune's fiscal Q2 earnings beat on October 28, where the company reported a loss of $0.54 per share versus the consensus $0.70 loss, a 22.9% beat. The company also announced the commercial launch of TUDRIQEV for advanced melanoma, with more than 15 institutions already prescribing the therapy. This marked the last pre-revenue quarter, and the market is now focused on the launch trajectory.
REPL EPS revision history → · Screener snapshot from 2026-10-29 →
FAQ: REPL
Why did REPL stock jump?
REPL stock jumped 24.3% after its forward EPS growth estimate was raised from 35.3% to 41.1% on October 29, 2026, driven by a Q2 earnings beat and the launch of TUDRIQEV.
What caused REPL's surge?
The surge was caused by a 22.9% earnings beat on October 28, 2026, and the commercial launch of TUDRIQEV, which has already been prescribed by more than 15 institutions.
Is REPL a buy after the rally?
REPL's investment case now hinges on the commercial success of TUDRIQEV; the stock has risen 24.3% since detection, and future growth depends on formulary wins and revenue conversion.
Why did DFH stock jump in November 2026?
DFH rose 22.8% (from $10.10 to $12.40) after its next-year EPS growth estimate was reported at 108.6% on November 3, 2026.
The homebuilder's stock gained as the company announced early participation results of a private exchange offer on November 5, which was seen as a positive step in managing its debt profile. The strong EPS growth estimate reflects expectations of a rebound in the housing market, with Dream Finders positioned to capitalize on favorable demographic trends and limited housing supply.
DFH EPS revision history → · Screener snapshot from 2026-11-03 →
FAQ: DFH
Why did DFH stock jump?
DFH stock jumped 22.8% after its next-year EPS growth estimate was reported at 108.6% on November 3, 2026, and the company announced early participation results of a private exchange offer on November 5.
What is DFH's EPS growth estimate?
DFH's EPS growth estimate for next year is 108.6%, indicating expectations for more than doubling earnings.
Is DFH a buy after the rally?
DFH's strong EPS growth estimate and debt management efforts are positive, but the stock's 22.8% rally may already reflect some of this optimism; consider housing market conditions.
Why did RYTM stock jump in November 2026?
RYTM climbed 20.6% (from $93.07 to $112.28) after its next-year EPS growth estimate was reported at 78.1% on October 29, 2026.
The gain was reinforced by a Q3 earnings beat on November 3, with a loss of $0.61 per share versus the consensus $0.68 loss, and revenue of $92.1 million that topped estimates by 9.1%. The company also received positive NICE guidance on November 4 for IMCIVREE in adults with Bardet-Biedl syndrome, expanding reimbursement in the UK. The launch of IMCIVREE for hypothalamic obesity is accelerating, with more than 700 patient start forms.
RYTM EPS revision history → · Screener snapshot from 2026-10-29 →
FAQ: RYTM
Why did RYTM stock jump?
RYTM stock jumped 20.6% after its next-year EPS growth estimate was reported at 78.1% on October 29, 2026, and the company beat Q3 estimates on November 3 with revenue of $92.1 million.
What caused RYTM's surge?
The surge was driven by a Q3 earnings beat, accelerating IMCIVREE sales (up 29% sequentially), and positive NICE guidance for expanded reimbursement in the UK.
Is RYTM a buy after the rally?
RYTM's strong revenue growth and expanding reimbursement support the bull case, but the stock has already gained 20.6% since detection; consider the commercial launch trajectory and pipeline.
Why did JBLU stock jump in November 2026?
JBLU gained 20.3% (from $3.05 to $3.67) after its next-year EPS growth estimate was reported at 54.6% on October 29, 2026.
The stock received a boost on November 5 when Deutsche Bank upgraded JetBlue to Buy from Hold, citing an improved near-term backdrop for airlines, including favorable supply trends and higher fares. The upgrade also highlighted JetBlue's upcoming product launches and the potential for a seasonal year-end rally. Additionally, JetBlue raised checked bag fees on November 3 to offset rising fuel costs.
JBLU EPS revision history → · Screener snapshot from 2026-10-29 →
FAQ: JBLU
Why did JBLU stock jump?
JBLU stock jumped 20.3% after its next-year EPS growth estimate was reported at 54.6% on October 29, 2026, and Deutsche Bank upgraded the stock to Buy on November 5.
What caused JBLU's surge?
The surge was driven by an EPS growth estimate of 54.6%, a Deutsche Bank upgrade to Buy, and industry-wide improvements including higher fares and favorable supply trends.
Is JBLU a buy after the rally?
JBLU's 54.6% EPS growth estimate and the analyst upgrade suggest improving fundamentals, but the stock has already risen 20.3% and remains sensitive to fuel costs and economic conditions.
Today's top performers highlight the market's receptiveness to upward earnings revisions, particularly in healthcare and consumer cyclical sectors, signaling a bullish sentiment that rewards early signs of fundamental improvement.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →